2022 iTOC Annual Meeting: September 22-24, 2022

Poster Presentation

Maik Pruess

September 22-24, 2022

Poster # P04.02
Poster Title: A high sensitivity, tumor-informed liquid biopsy platform, designed to detect minimum residual disease at part per million resolution
Presenter: Maik Pruess, PhD

Satellite Symposium

Maik Pruess

September 23 at 2:30 – 3:00 PM CEST

Maik Pruess PhD
Senior Field Application Scientist
Personalis, Inc.

Personalis NeXT Platform
Enabling the future of precision oncology with comprehensive, unprecedented tumor profiling solutions for both tissue and liquid biopsy

  • Combining highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics, ImmunoID NeXT™ provides a multidimensional view of the tumor and the tumor microenvironment from a single tumor sample preparation
  • A clinical case study in a cohort of late-stage melanoma patients demonstrating how the integration of neoantigen burden, HLA LOH, and Antigen Presentation Machinery (APM) mutational data formed a composite biomarker that more accurately predicted response to checkpoint blockade than other markers
  • In parallel, specimens may be processed using NeXT Personal™, an ultrasensitive tumor-informed liquid biopsy assay, designed to detect molecular residual disease and cancer recurrence at the earliest timepoints, with simultaneous variant tracking for additional insight into disease progression

Connect with us at iTOC9 2022